Sanofi strikes $ 9.1 billion for Blueprint Medicines!

Sanofi strikes $ 9.1 billion for Blueprint Medicines!

USA - Sanofi announced an important step in the pharmaceutical industry today: The French company plans to take over the US pharmaceutical company Blueprint Medicines for a total of $ 9.1 billion, which corresponds to around 8 billion euros. The takeover price of $ 129 per share includes a surcharge of 27 percent on the final course of Blueprint on Friday. This business aims to strengthen Sanofi's position in the growing area of ​​rare immunological diseases, reports suedkurier.de .

Sanofi boss Paul Hudson described the takeover as a strategic step to expand the portfolio for rare medicines and immunology. By buying, Sanofi not only receives the expertise of Blueprint, but also the drug Avapritinib you developed, which is approved in the USA and the EU for the treatment of rare immune diseases. Avapritinib represents the only approved drug for a rare immune disease with changed mast cells and could significantly expand Sanofi's product range.

Overview of Blueprint Medicines

Blueprint Medicines has established itself as a specialist in rare immune diseases and cancer. The Ayvakit company is particularly well known, the only approved drug for the treatment of systemic mastocytosis (SM). This product has developed as a lucrative niche with increasing sales and a growing patient base. In addition to Ayvakit, Blueprint also brings other promising active ingredient candidates such as Elenestinib and Blu-808, which could strengthen the immunology division in the Sanofi portfolio, such as Finanztrends.de explained.

The takeover could also enable Blueprint to use the existing networks; The company is well networked with allergists, dermatologists and immunologists. These connections will be important for Sanofi to promote research and sales in the field of immunology. The conclusion of the takeover is planned for the third quarter of 2023 and is expected to have no significant effects on the financial forecast of Sanofi for 2025

challenges and opportunities in the area of ​​rare diseases

The market for medicines against rare autoimmune diseases is characterized by close sales markets and high development costs. According to the vfa.de , diseases such as myastenia gravis and systemic sclerosis can only be found in about two out of 10,000 citizens. Despite the market exploration, which is granted by the Orphan drug status over a period of ten years, the development of such medication remains risky and expensive.

Sanofi plans to invest in growth fields such as immunology by the acquisition of Blueprint, which can be expected to have positive effects on profit margins and the profit per share in the medium and long-term. The transaction is financed by existing funds and new debts.